Compare ING Groep NV (ING) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Sana Biotechnology Inc — how do they compare? ING Groep NV trades at $35.6 (market cap $101.22B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: ING Groep NV is far larger — about 89.6× Sana Biotechnology Inc's market cap, and ING Groep NV pays a 3.73% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ING | SANA | |
|---|---|---|
Market Cap | $101.22B | $1.13B |
Sector | Financials | Health |
52-Week High | $35.92 | $5.92 |
52-Week Low | $23.66 | $2.68 |
Dividend Yield | 3.73% | — |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING Groep (ING) trades at $35.61, up 1.05% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $0.79 exceeding expectations. Revenue growth remains stable at $22.9B for 2025, supported by a robust 28.34% net income margin and 13.49% ROE. Recent guidance upgrades and strategic acquisitions in wealth management signal management confidence in future growth prospects.
The outlook remains positive with 62.5% analyst buy ratings and technical indicators supporting further upside. Key risks include negative operating cash flows and European banking sector volatility. The stock's attractive 13.24 P/E ratio and dividend yield provide value appeal, though investors should monitor cash flow trends and interest rate sensitivity.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
